Moreover, SCLC cell lines have already been tested against seven of these drugs (CancerRxGene database40), namely dasatinib (targeting EPHA2), vorinostat (targeting HDAC1), imatinib, pazopanib, sorafenib, sunitinib and tivozanib (all targeting KIT). This evidence concerns the gene HDAC1 and small cell lung carcinoma.